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THERAPEUTIC VACCINES FOR LYMPHOMA Dr Ronald Levy,
Stanford University School of Medicine, USA
The antigen binding receptor on the surface of a lymphocyte is composed of protein
chains, each with constant and variable domains. A unique combination of variable
regions is formed by genetic rearrangements which occur during lymphocyte differen-
tiation and which mark the clonal progeny of each original mature B cell or T cell.
Malignant lymphomas have antigen binding receptors which are unique to each tumor
and are expressed uniformly by all members of the malignant clone. These receptors
can be isolated from the tumors by hybridoma or by molecular cloning techniques.
Monoclonal antibodies generated against the unique (idiotypic) portion of receptors
from B cell tumors have been able to induce complete and durable remissions in
patients with lymphoma. Alternatively, it is possible to use the receptors as an active
vaccine to induce an immune response in the host against his own tumor. Animals
bearing established tumors can be cured by a combination of chemotherapy and idio-
type vaccination (J Immunol. 141:3227–3233, 1988). Moreover, patients with B cell
lymphoma be induced to make immune responses against the idiotypes expressed by
their tumors, and these immune responses have been associated with tumor regression
(N Eng J Med 327:1209–1215). Clinical trials are under way in patients with
Follicular Lymphoma in which idiotype vaccines custom made from each patient’s
tumor are prepared and administered after chemotherapy induced remission. The
results of these ongoing trials will be presented and novel methods of vaccine produc-
tion will be discussed.
S2 
NICE THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE,
M.D. Rawlins, 90 Long Acre, Covent Garden, London WC2E 9RZ
The National Institute for Clinical Excellence has been established to provide NHS
health professionals with advice on delivering the highest standards of care to their
patients. In delivering this, NICE will provide guidance in three areas:
• use of individual technologies after “appraisal”
• management of specific clinical conditions (clinical guidelines and referral 
protocols)
• clinical audit methods
Appraisal of technologies will indicate whether they are both clinically and cost
effective; and whether, how, and when they should be used within the NHS. Guidance
will be accompanied by simple methods of clinical audit.
Clinical management programmes will cover both approaches to individual con-
ditions (clinical guidelines) and the circumstances where specialist advice should be
sought (referral protocols). Both will also be accompanied by simple approaches to
clinical audit.
Clinical audit. The Institute will further the development of clinical audit by
proposing methodologies in the areas in which it has provided guidance; by acting as
an information resource to NHS staff; by supporting ‘core audit’ with professional
bodies; and by supporting national ‘sentinel’ audits.
• NICE’s agenda is ambitious and its first priorities include:
• establishing the Institute
• starting its work programme
• gaining the confidence of its stakeholders
S3 
IS THERE A FUTURE FOR LUNG CANCER SCREENING? Nick
Wald, St Bartholomew’s Medical School, London EC1M 6BQ, UK
ABSTRACT NOT RECEIVED
S4 
ORGANISATIONAL AND TECHNICAL ADVANCES IMPROVE THE
RESULTS IN LUNG CANCER: A SURGEON’S VIEW Francis Wells,
Papworth Hospital, Papworth Everard, Cambridge CB3 8RE, UK
ABSTRACT NOT RECEIVED
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S5
THE IMPLICATIONS AND OPPORTUNITIES OF THE CHART
TRIAL IN THE TREATMENT OF NON-SMALL CELL LUNG
CANCER MI Saunders*, Mount Vernon Hospital, Rickmansworth Road,
Northwood, HA6 2RN, UK
Purpose To evaluate the implications of the randomised controlled trial of CHART
versus conventional radiotherapy in the treatment of locally advanced non-small cell
lung cancer.
Method A total of 563 patients were entered into the trial between April 1990 and
April 1995. The patients were randomised to conventional radiotherapy 60 Gy in 6
weeks or CHART where they received 54 Gy in 36 fractions treating three times a day
on consecutive days. The results of the study are considered with reference to
survival, locoregional control, metastasis-free survival, acute and late morbidity,
quality of life and socio-economic assessment.
Results Survival: There is a significant long term improvement in the survival for
the CHART arm with a 2 year survival probability of 30% compared to 21% for the
conventional arm for the whole group (p = 0.008) and 33% versus 22% in those with
squamous cell carcinoma (p = 0.0007). This increase in survival was achieved by
gaining a significant improvement in locoregional control and an increase in the
metastasis-free survival. Two years metastasis-free survival for those with squamous
cell carcinoma was 52% in CHART and 42% with conventional radiotherapy.
Dysphagia was the major acute morbidity and came on earlier with CHART, was
more severe but settled satisfactorily in patients in both arms of the study. Frequency
and severity of radiation pneumonitis was slightly less in the CHART arm.
Considering late morbidity there was no incidence of radiation myelitis and at two
years only 7% and 5% were considered to have symptoms of dysphagia related to
radiotherapy in the CHART and conventional arm. There was no trend for pneu-
monitis to be more troublesome in CHART compared to conventional radiotherapy.
There was no difference between the regimes in the short or long term when quality of
life was considered.
Socio-economic factors were carefully considered and taking the data from all
sources and looking at the difference between CHART and conventional radiotherapy
the study showed that CHART was more expensive than conventional radiotherapy but
the cost differential is only £697.79 at 1994 levels. A further analysis of the data by
Soren Bentzen, as yet unpublished, has shown looking at the difference between the
two curves there is again a life expectancy from CHART (truncated at 4 years) is 101
days. Cost per life year gained by the use of CHART to 4 years is £2,585. This makes
CHART extremely cost-effective when compared to other interventions in medicine.
Conclusion CHART radiotherapy gives a true therapeutic benefit when compared
to conventional radiotherapy. As the socio-economic study suggested it is cost effec-
tive particularly when compared to other interventions currently used in oncology.
S6
DOES CHEMOTHERAPY IMPACT ON THE OUTLOOK OF NON-
SMALL CELL LUNG CANCER? Heine H Hansen, Dept of Oncology,
Finsen Centre, National University Hospital, Rigshospitalet, Copenhagen,
Denmark
While there is no established role for adjuvant therapy including chemotherapy in
connection with surgery for stage I and II patients, the picture is different for patients
presenting with stage III and stage IV non-small cell lung cancer. For stage III patients
induction combination chemotherapy with platinum-containing regimen followed by
radiotherapy has shown superiority to radiotherapy alone in both individual trials and
meta-analyses. The latter demonstrated a 13% reduction in risk of death and an
absolute benefit of 4% at 2 years for the combined modality treatment versus radio-
therapy alone. Survival data from recent randomized trials have also indicated superi-
ority for concomitant chemotherapy and radiotherapy rather than radiotherapy alone
in stage III patients. With respect to neoadjuvant chemotherapy followed by surgery in
selected stage III patients, 2 minor studies have demonstrated significant survival
advantages for the combined modality approach.
Almost 50% of the patients with NSCLC present with advanced disease (stage IV)
and for patients with good prognostic factors combination chemotherapy with 2 or 3
drugs results in improved survival and quality of life. In patients relapsing after initial
treatment, often platinum containing chemotherapy, docetaxel has shown to improve
survival and quality of life compared with best supportive care in one study.
Overall the results of non-surgical treatment of NSCLC remain highly unsatisfac-
tory in spite of the introduction of a number of new agents in the early 1990s. New
treatment approaches are needed and under investigation.
S7
MOLECULAR GENETICS OF DRUG SENSITIVITY AND
RESISTANCE IN A MOUSE LYMPHOMA MODEL Clemens A
Schmitt, Jordan Fridman and Scott W Lowe, Cold Spring Harbor Laboratory,
Cold Spring Harbor, NY 11724, USA
To develop physiological in vivo models for studying tumor cell radio- and chemosen-
sitivity, we are investigating the therapeutic response of spontaneous lymphomas
occurring in the Em-myc transgenic mouse. These animals constitutively express c-
myc in the B-cell lineage and typically succumb to B-cell lymphoma with associated
leukemia. We hypothesized that the Em-myc transgenic would be a tractable model,
since: (i) tumor burden can be easily monitored by lymph node palpation or blood
smears; (ii) lymphomas are detectable long before the animal dies, (iii) large numbers
of pure tumor cells can be isolated from mice undergoing therapy, (iv) therapy is
performed in immunocompetent mice, and (v) lymphoma cells readily adapt to culture
and can be transplanted into syngeneic mice. We have characterized the response of
Em-myc lymphomas to several anticancer drugs, and have developed methods to facil-
itate the analysis of genetic factors involved in drug sensitivity and resistance.
Specifically, we have examined the impact of INK4a/ARF mutations, p53 mutations,
and Bcl-2 overexpression on the treatment sensitivity of Em-myc lymphomas. These
studies demonstrate that: (i) disruption of the INK4a/ARF locus produces aggressive,
chemoresistant tumors by disabling p53, (ii) disruption of apoptosis during the course
of tumor development can simultaneously produce drug-resistant tumors, (iii) the Bcl-
2 oncoprotein produces a multi-drug resistant phenotype when assayed in short-term
culture or in vivo, and (iv) the impact of Bcl-2 on drug resistance is reduced when
assayed in culture-adapted cells and completely missed in the standard clonogenic
survival assay. Our results highlight the importance of physiological test systems to
study treatment sensitivity, and establishes a strategy for producing genetically-
defined lymphomas to evaluate compounds directed against specific lesions. Of note,
INK4a/ARF and p53 mutations are associated with reduced treatment sensitivity in
human hematologic malignancies, implying the information obtained from our model
will be applicable to human cancers.
S8 
CONVERGING ONCOGENES IN CANCER Gerard Evan, University
of California, San Francisco, Comprehensive Cancer Center, 2340
Sutter Street, San Francisco, California 94143-0128. 
Cancers arise through accumulation of mutations that compromise control of cell
proliferation, differentiation, cell adhesion and apoptosis. Deregulation of the cmyc
proto-oncogene is a ubiquitous neoplastic mutation that disrupts cell growth control
and renders cells independent of mitogens for cell cycle progression. However, acti-
vation of c-myc also sensitises cells to apoptosis. We believe that this innately contra-
dictory action of c-myc acts as a restraint to the propagation of neoplastic cells within
the soma, but this has never been directly demonstrated in vivo. We have therefore
constructed mice harbouring a switchable Myc protein in specific tissues – specifi-
cally, T lymphocytes, pancreatic islets cells and suprabasal keratinocytes – to permit
analysis of the immediate as well as the delayed consequences of c-Myc activation in
a normal somatic cell. In pancreatic ß cells, c-Myc activation induces ~100% entry of
cells into cell cycle. However, this is accompanied by massive apoptosis that over-
whelms proliferation leading to islet involution and acute diabetes. Thus, neoplasias
cannot arise in ß cells without early suppression of apoptosis. Indeed, co-expression of
Bcl-2 blocks the apoptosis and, together with c-Myc, rapidly leads to dramatic ß cell
hyperplasia. By contrast, activation of c-Myc in suprabasal keratinocytes triggers cell
proliferation and blockade of keratinocyte differentiation with no ‘compensatory’
apoptosis. The result is a complex neoplastic papilloma phenotype exhibiting hyper-
plasia, dysplasia, neo-angiogenesis and parakeratosis. The absence of apoptosis in
these papillomas is not because c-Myc lacks the facility to trigger keratinocyte cell
death. Rather, it appears to be because of the presence of excess survival signals in
intact epidermis: c-Myc is highly effective at inducing apoptosis in transgenic
keratinocytes explanted into cell cultures devoid of survival factors. The strong impli-
cation from this is that, unlike ß cells, suppression of apoptosis through mutation is
not required for the establishment and progression of superficial skin tumours.
However, it is of note that c-Myc-induced papillomas remain completely non-invasive
yet in the absence of p53 they rapidly invade the underlying dermis and mesenchyme.
As p53 is required for efficient c-Myc-induced apoptosis in keratinocytes, the primary
role for p53 loss may be to allow survival of invading keratinocytes when migrating
into an ‘inappropriate’ trophic environment. These two transgenic models exemplify
how different ‘rules’ govern tumorigenesis and progression in tissues reflecting
differing architectures and functions and may shed light on why neoplasms in
differing locations adopt preferred evolutionary routes to malignancy. Invited Papers 5
S9
MODELLING INTESTINAL NEOPLASIA W Dove, A Bilger, R
Cormier, K Gould, K Haigis, R Halberg, A Lillich, A Merritt, A
Shedlovsky, A Shoemaker and A Thliveris, McArdle Laboratory and
Laboratory of Genetics, University of Wisconsin, Madison, WI 53706 USA
The Min mouse strain, predisposed to multiple intestinal polyposis, is heterozygous
for an ENU-induced nonsense allele of Apc, the mouse homolog of the human gene
Adenomatus polyposis coli. The initial phase of studies with Min and other targeted
alleles of Apc, worldwide, has generated both advances and challenges in reaching a
deeper understanding of human colon cancer.
• The multiplicity of adenomas in mice carrying the Min allele is strongly affected
by the genetic background, varying over two orders of magnitude. Studies in
different laboratories can be compared more rigorously when both the Apc allele
and the genetic background are standardized. Can mouse models with validated
genetic constitution be effectively distributed worldwide?
• Adenoma formation commonly involves loss of expression of the wildtype Apc
allele, but not always through allele loss or intragenic mutation. What Apc-
silencing mechanisms exist?
• Adenomas are commonly polyclonal in structure, with each contributing line-age
showing Apc loss. Is polyclonality passive or does it involve active cooperation
in the transition to or maintenance of neoplasia? What is the primary rate of
allele-loss at the Apc locus?
• The maintenance DNA methylase positively regulates the net growth rate of
adenomas. What are the salient growth-regulatory genes through which DNA
methylation operates?
• The p53 gene modestly affects adenoma multiplicity, but p53 mutations lead to a
small set of locally invasive intestinal tumors in Min mice. Can invasive and
metastatic intestinal tumors be made a more prominent component of the tumor
spectrum in Min and other mutant mice?
• The multiplicity and net growth rate of adenomas is affected by polymorphic
modifier loci. The first such locus to be investigated in great detail, Mom l,
involves a secretory phospholipase synthesized by Paneth cells and goblet cells
in resistant strains. However, there is at least one other gene that accounts for the
resistance phenotype in the Mom l region. Can the complexity of modifier loci be
reduced, for example by point mutagenesis of the germline? Does the secretory
phospholipase affect colonic adenomas in the human?
• One positive cellular marker has been found for the proliferative compartment
within intestinal crypts and intestinal tumors in the mouse: ROSA11. Can diag-
nostic cellular markers be developed to discriminate among intestinal tumors of
differing biological source and potential?
Dove WF, Cormier RT, Gould KA, Halberg RB, Merritt AJ, Newton MA and
Shoemaker AR (1998) Phil Trans R Soc, Lond B, 353: 915.
S10
MODELING CANCER IN THE MOUSE Tyler Jacks, Howard
Hughes Medical Institute, Center for Cancer Research,
Department of Biology, Massachusetts Institute of Technology, Cambridge,
MA 02139 USA
The advent of gene targeting technology in mouse embryonic stem (ES) cells has
made it possible to introduce specific mutations into the murine germline. Over the
past several years, we have used this technology to mutate the murine homologs of a
series of human genes implicated in tumor development, specifically the tumor
suppressor genes Rb, p53, Nf1 and Nf2. These mutant animals have been useful as
models for certain human familial cancer syndromes caused by the inheritance of a
single mutant allele of a given tumor suppressor gene, as a means to address the role
for these genes in normal development, and as a source of primary cells and cell lines
with which to examine tumor suppressor gene function in vitro. Recently, we have
also developed a novel mouse strain carrying a targeted mutation in the K-ras proto-
oncogene, which causes predisposition to tumors of the lung and other sites. These
mutant strains will be described with an emphasis on our attempts to address species-
specific differences in the response to inherited mutations in cancer-associated genes
as well as our efforts to construct more accurate murine models of human cancer, both
genetically and histopathologically.
S11
NEW MOUSE MODELS FOR HUMAN CANCER Anton Berns,
Division of Molecular Genetics and Centre of Biomedical Genetics,
The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam,
The Netherlands. e-mail: tberns@nki.nl
Gene inactivation studies are invaluable in assessing the function of oncogenes and
tumor suppressor genes in development and malignant growth. However, detailed
analysis of the role of tumor suppressor genes in these processes using the conven-
tional knockout mouse models is often hampered by embryonic lethality or develop-
mental aberrations.
To circumvent these complicating factors associated with loss-of-tumor suppressor
gene function we have generated a series of conditional tumor suppressor gene
knockout mice using the Cre/Lox system. We have explored methods to switch these
genes off in a time-controlled and tissue specific fashion. Both transgenesis and
somatic gene transfer was used to express Cre recombinase in the desired tissues. This
technology permits us to induce specific tumors, and to correlate specific genetic
lesions with phenotypic characteristics. Since we now can induce multiple defined
mutations within the same cell of a tissue we can mimic closely the genetic aberra-
tions found in tumors in man. This will facilitate the testing of intervention strategies
targeted to distinct pathways disrupted in the model in conjunction with a range of
other mutations. To follow tumor growth in vivo we have implemented new imaging
techniques.
These compound mutant mice are also a valuable source of cell lines that can be
tested with respect to parameters that are better studied in vitro such as growth, cell
cycle regulation, response to irradiation, resistance to apoptosis, and genomic insta-
bility. Examples will be discussed.
S12
INVESTIGATION INTO THE PHARMACODYNAMICS OF THE
BROAD-SPECTRUM NEUROPEPTIDE GROWTH FACTOR
ANTAGONISTS IN THE EARLY CLINICAL  DEVELOPMENT OF
ANTAGONIST G S.Clive, ICRF Medical Oncology Unit, Western General
Hospital, Crewe Road, Edinburgh, EH4 2XU.
Small cell lung cancer (SCLC) cells secrete neuropeptides that act as autocrine growth
factors. Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2 (Ant G), a substance P (6-11) ana-
logue, antagonises a broad spectrum of neuropeptides, including vasopressin (AVP),
gastrin releasing peptide (GRP) and bradykinin (BK), has in vivo activity in SCLC
models and was selected for clinical development. A phase I trial was performed, under
the auspices of the CRC Phase I/II Committee (CRC 90-08), in 2 stages. The primary aim
of stage I was to achieve an end of infusion Ant G plasma concentration (Cmax) of 10mM,
a concentration associated with anti-tumour activity pre-clinically. Given by 
6-hour, 3 weekly infusion through a central line, dose was escalated from 2–300 mg/m2
with 15 patients entered (12M: 3F; age 36–65 (median 59), PS median 1). Cmax of 10mM
was exceeded in 3/3 patients at 300mg/m2 (13–24 mM). In stage 2, dose intensity was
increased (weekly infusion) and forearm blood flow (FBF) changes as measured by
venous occlusion plethysmography were incorporated as a pharmacodynamic endpoint.
9 patients (5M: 4F; age 34–75 (median 54), PS median 1) were entered in 3 dose levels,
achieving Cmax 19–45(M at the highest (400mg/m2) dose. Toxicity related to facial
flushing and was not dose limiting. FBF studies were performed in 8/9 patients. Intra-
arterial infusions of neuropeptides, substance P (SP) and bradykinin (BK), were
performed before and during Ant G infusion. Ant G caused a significant (p<0.05) reduc-
tion in the arterial dilatory effects of SP (66%) and BK (33%). Although the validity of
these studies as surrogate markers of activity of Ant G requires confirmation, biological
activity of Ant G was demonstrated in patients at Cmax at which preclinical antitumour
activity had been seen. This was accepted for completion of the phase I trial without defi-
nition of the MTD and a dose of 400 mg/m2 has been suggested for phase II studies. The
mitogenic properties of SP in SCLC remain undefined whereas GRP and AVP are recog-
nised autocrine growth factors in SCLC and Ant G is a potent antagonist of both in vitro.
Therefore the effects of GRP and AVP on FBF in healthy volunteers was examined. GRP
caused consistent, dose-dependent vasodilatation at doses that could be given intra-
arterially without toxicity, a finding that has not previously been demonstrated. Therefore
it would be a suitable neuropeptide for use in FBF studies in patients receiving Ant G.
AVP did not demonstrate a consistent response in FBF studies. However, AVP is known
to cause aggregation of platelets in platelet rich plasma (PRP) and the effects of Ant G on
this were examined in volunteer PRP. Ant G was consistently and selectively shown to
inhibit AVP-induced platelet aggregation in a competitive, dose-dependent manner. This
assay is relatively non-invasive, would enable a variety of time-points to be examined
and would be attractive as a pharmacodynamic measure for inclusion in the further clin-
ical development of Antagonist G.6 Invited Papers
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REGULATION OF ETS TRANSCRIPTION FACTOR ACTIVITY
Shen-Hsi Yang1, Alex Galanis1, Elaine Vickers1, Amanda Greenall2,
Paula Yates2, Nicola Willingham2 and Andy Sharrocks1, 1School of Biological
Sciences, University of Manchester, Manchester, UK. 2School of
Biochemistry and Genetics, The Medical School, University of Newcastle
Upon Tyne, Newcastle Upon Tyne, UK
Several members of the ETS-domain transcription factor family have been implicated
in tumorigenesis. For example, the founder member Ets-1 is a proto-oncogene.
Further ETS-domain proteins are deregulated by either overexpression or rearrange-
ment of their genes, resulting in a variety of different types of cancers. In the majority
of these tumours, the changes seen in individual proteins, generally result in retention
of their intact DNA binding domains but either deletion or alterations in their regula-
tory regions.
The ETS-domain transcription factors are often regulated by MAP kinase path-
ways, components of which are targets for deregulation during tumour formation. In
recent years, our understanding of the molecular function of different ETS-domain
proteins has increased substantially. Our recent studies emphasise the importance of
the ETS-domain and the regulatory regions in their function and hence extend our
understanding of the molecular causes of tumorigenesis.
The ETS-domain transcription factor Elk-1 and the related proteins SAP-1 and
SAP-2 play a pivotal role in the regulation of c-fos in response to extracellular signals.
We have demonstrated that divergent MAP kinase pathways transduce these signals
and their specificity of action involves the complex interplay of a series of
docking/targeting motifs. Phosphorylation of the transcription factors results in their
activation. One mechanism by which this occurs is by changing the conformation of
the proteins, which potentially uncovers/masks interaction surfaces for coregulatory
proteins. Recent data indicate that this is indeed a distinct possibility and coacti-
vator/corepressor complexes can be recruited following phosphorylation of transcrip-
tion factors by MAP kinases. Further complexities in the activation/repression
mechanisms have also been revealed. Finally, novel links have been uncovered
between the Id helix-loop-helix proteins and ETS transcription factors where the Id
proteins downregulate the activity of ETS-domain transcription factors.
Collectively, our data enhance our knowledge of how this important class of tran-
scription factors functions at the molecular level, how they interact with the MAP
kinase pathways and how the activities of ETS-domain proteins might be disrupted
during tumorigenesis.
S14
TECHNOLOGICAL DEVELOPMENTS IN EXTERNAL BEAM
RADIOTHERAPY PC Williams* and JM Wilkinson, North Western
Medical Physics, Christie Hospital, Manchester M20 4BX, UK
The technology for radiotherapy has developed continually since the introduction of
the linear accelerator. Certain landmark developments include the introduction of
computerised treatment planning based on CT imaging and the introduction of multi-
leaf collimation facilitating practical application of 3D conformal therapy.
Conformal radiotherapy is not a well defined term but includes any treatment tech-
nique which intends to make the treated volume closely match the target volume has
been termed conformal radiotherapy. The purposes of conformal therapy are either to
reduce the target volume and hence allow the possibility of dose escalation or to
minimising the complication rate by reducing the volume of healthy and susceptible
tissue included in the treated volume.
Conformal therapy demands high precision in the localisation, planning and
delivery of treatment which then needs to be verified to ensure that the geometric and
dosimetric requirements of each treatment are achieved. Electronic portal imaging has
addressed this requirement.
Standard conformal therapy is now widely, but not universally, available. Studies
have shown that significant benefits can be realised by such techniques which exploit
the ease at which treatment beams can be shaped, by an MLC, to match the projects of
targets to be irradiated and sensitive structures to be shielded.
Static use of an MLC generates 3 dimensional target volumes by the intersection of
beams shaped in 2 dimensions and projected from different directions. It does not
address the problem of generating non uniform intensities to compensate for the
varying attenuation and scattering in tissues through which the radiation must pass,
nor does it address the problem of shaping the treatment volume in the third dimen-
sion as is required if the target volume is invaginated in the planes normal to the rota-
tion axis of the accelerator.
Both these problems can be addressed by the use of Intensity Modulated
Radiotherapy (IMRT) in which the positions of the Multileaf collimator are varied
during irradiation. The current state of development of IMRT will be outlined with
particular reference to the clinical applications that have been implemented.
Following the full implementation of IMRT. Our ability to deliver accurately
highly modulated beams will exceed our ability to define the target tissues and to
verify their position during irradiation. Further development of Image Guided
Radiotherapy will then be justified.
S15
CLINICAL IMPLEMENTATION OF INTENSITY MODULATED
RADIOTHERAPY W De Neve, Division of Radiotherapy, Ghent
University Hospital, B-9000 Ghent, Belgium
Intensity modulated radiotherapy (IMRT) is the hot topic in radiotherapy translational
research. IMRT allows us to customize the dose distribution to maximize the proba-
bility of uncomplicated local control. Our initial focus for clinical implementation was
on head and neck and prostate cancer.
Methods IMRT planning consisted of a mixture of forward (class solution)2 and
inverse [desired dose distribution decomposition; intensity optimization elements (W.
De Neve, Presidential Course, ASTRO 1999]3,1,2. At the end stage of planning,
segments were linked for fast sequential delivery by an SL-18-MLCi or SL-25-MLCi
(Elekta), with a dynamic multileaf collimator forced in step and shoot mode2.
Results Between 1/9/1996 and 31/10/1999, 32 patients with cancer in the head and
neck region were treated using segmental IMRT. Eleven of these patients were re-irra-
diated for inoperable relapses or second primaries in previously irradiated regions. All
re-irradiated patients had severe symptoms. For 8 of 10 evaluable patients, palliation
was achieved. Median duration of response was 9 months. Median survival calculated
from the onset of re-irradiation was 15 months. The cause of death was intercurrent
(intestinal hemorragh) in one patient and related to disease progression in five
patients. Subcutaneous fibrosis was reported in seven patients; temporomandibular
joint impairment and laryngeal edema each in one patient. In spite of cumulative
doses as high as 136 Gy, no cases of cranial nerve palsy, arterial rupture or bone
necrosis were observed. From July 1998 till December 1999, 31 patients received
IMRT for prostate cancer to a prescription median dose of 76 Gy in 36 fractions. The
main goal of IMRT was to keep the maximal rectal dose at 72 Gy. No acute toxicity
above grade 2 was observed. For head and neck tumours, the delivery of 20–50
segments per session took 12–22 minutes, including the time required for patient
setup and portal imaging. Prostate IMRT (13–20 segments) was delivered in 6–12
minutes depending on the ease of patient setup and on portal imaging.
Discussion During recent years, MLC technology capable of delivering multiseg-
ment or dynamic IMRT became available. Like all other centers that have applied
IMRT with large MLCs (i.e. not NOMOS MiMiC) during the last decade, we had to
solve the IMRT planning problem in-house which involved the development, inter-
facing maintenance and quality assurance of IMRT planning tools. Actually, about
10% of our patients receive IMRT making the projected total number of IMRT treat-
ments about 100 for the year 2000. With the fast progress in the field, we feel the need
to participate in inter-institutional, preferably randomized IMRT studies.
1 W De Gersem et al (1999) Int J Radiat Oncol Biol Phys 44: 461–468
2 W De Neve et al (1999) Radiother Oncol 50: 301–314
3 C. De Wagter et al (1998) Radiother Oncol 47: 69–76
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BRACHYTHERAPY FOR LOCALISED PROSTATE CANCER
Dr D Ash, Cookridge Hospital, Leeds, UK
As a result of PSA testing an increasing number of patients with localised prostate
cancer are presenting for treatment; many are less than 70 years old and suitable for
radical local therapy. The conventional alternatives are external beam radiotherapy or
radical prostatectomy. New techniques of brachytherapy now offer a much less inva-
sive alternative with a lower risk of side effects.
The majority of patients suitable for radical prostatectomy are also suitable for
brachytherapy. The selection factors that determine probability of PSA control are the
same ie presenting PSA, Gleason grade and stage.
The factors which determine functional outcome are different. For prostatectomy,
age and co-morbidity are important whereas it is less of a problem for brachytherapy.
For brachytherapy significant outflow obstruction may increase the risk of obstruction
and delayed resolution of urethral side effects. For both treatments the quality of the
intervention has a significant bearing on outcome. For surgery the margin status is
highly significant. For brachytherapy the dosimetric quality which confirms that the
tumour has been enclosed within the treatment isodose is also highly significant.
When comparing treatments it is therefore necessary to know not only what the pre-
treatment characteristics are but also the quality of the intervention.
Selected patients treated by high quality dosimetry controlled brachytherapy often
leave hospital the same or the next day after the implant and many are back at work
within seven days. The risk of incontinence is less than 1% and the risk of impotence
approximately 30%. At ten years approximately 80% of good prognosis patients
remain biochemically controlled. Because of the convenience, low risk profile and
equivalent outcome brachytherapy is preferable to radical prostatectomy for a high
proportion of patients.Invited Papers 7
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CHEMO-RADIOTHERAPY: IN PURSUIT OF THE MYTHICAL
FREE LUNCH Alastair J Munro, Dept of Radiotherapy, Ninewells
Hospital and Medical School, Dundee DD1 9SY, UK
A succession of clinical trials comparing radiotherapy alone with radiotherapy plus
synchronous chemotherapy have suggested that combined treatment improves both
local control and survival. These results suggest, at face value, that there may be a
truly supra-additive interaction between drugs and radiation. More detailed analysis of
the data is less convincing. In trials of chemo-radiotherapy in cancers of the head and
neck the improvement in local control and survival is paralleled by an equivalent
increase in acute toxicity. The results from the recent, much publicised, studies in
cancer of the cervix are similar. In randomised studies of chemo-radiotherapy in
cancers of the anus and rectum there is, again, a higher rate of acute toxicity with
combined treatment. There is also a disconcerting increase in non-cancer deaths,
suggesting that late effects of treatment may contribute to an increase in mortality
with combined treatment. The overall conclusion is that, before wholeheartedly
embracing combined chemotherapy and radiation, we need to have better data on
acute toxicity, on late effects and on patients’ views concerning any trade-offs
between the benefits and harms associated with combined treatment. For the moment
at least, we are left wondering whether the apparent benefits achieved using combined
treatment could have been achieved with radiation alone, simply by increasing the
dose.
S18
INTEGRATING THE CELL DEATH PATHWAY Stanley J
Korsmeyer, Dana-Farber Cancer Institute, One Jimmy Fund Way,
Rm SM758, Boston, Massachusetts 02115, USA
BCL-2 has the novel function of blocking the programmed death of cells. BCL-2
protein duels with its counteracting partner known as BAX. An expanding family of
BCL-2 related proteins shares homology clustered within four conserved regions
called BCL-2 homology (BH) 1 through 4. These novel domains control the ability of
these proteins to dimerize and function. Following a death stimulus, the monomeric,
cytosolic BAX translocates to mitochondria where it is a homodimerized, integral
membrane protein that activates apoptosis. BAD resides more proximal in the
pathway and determines the effectiveness of BCL-2 or BCL-XL. In the presence of
survival factor IL-3, cells phosphorylated BAD on two serine residues embedded in
14–3–3 consensus-binding sites. This frees BCL-XL to repress cell death. The rapid
phosphorylation of BAD connects a proximal survival signal with the BCL-2 family,
utilizing distinct kinases to inactivate BAD by selective phosphorylation of Ser112 or
Ser136. PKA, which is tethered to mitochondria by an A-Kinase Anchoring Protein
(AKAP), is responsible for the BAD Ser112 phosphorylation, representing a focused
interaction that inactivates BAD at its target organelle. BID possesses sequence
homology only at the BH3 domain and is found in both cytosolic and membrane loca-
tions. A multidimensional NMR structure indicates p22 BID has a similar a helical
structure to BCL-XL and undergoes structural changes upon activation. An intact BH3
domain of BID is required for it to bind BCL-2 or BAX as well as to promote apop-
tosis BH3-only molecules support BH3 as the minimal death domain and are candi-
dates to connect with proximal signal transduction. TNFa and FasL induce a
Caspase-8-mediated cleavage of the cytosolic, inactive p22 BID to create a predomi-
nant p15 BID that translocates to mitochondria as an integral membrane protein. P15
BID appears to be required for the release of cytochrome c. Bid-deficient mice proved
resistant to Fas-induced hepatic apoptosis, indicating it is a singularly important
Caspase substrate. BCL-2 family serves as a checkpoint in the cell death pathway in
which activation of pro-apoptotic members such as BAX, BAD or BID result in a
conformational change, a translocation from cytosol to mitchondria and the initiation
of an apoptotic program including Caspase activation and mitochondrial dysfunction.
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MOLECULAR REMISSION IN FOLLICULAR LYMPHOMA
THEORETICAL CONCEPT OR THERAPEUTIC GOAL? Dr A
Rohatiner, Dept of Medical Oncology, St. Bartholomew’s Hospital, London
EC1A 7BE, UK
With conventional therapy, follicular lymphoma remains demonstrably incurable for
most patients; an experimental approach is therefore justified. Recognition of the
association between follicular lymphoma and the t(14;18) translocation and the possi-
bility of detecting residual disease at the molecular level using PCR analysis, has led
to the concept of ‘molecular remission’. If the presence of PCR-detectable, residual
t(14;18) containing cells is used as a surrogate marker for the disease activity, PCR
analysis can be used to access the efficacy of a treatment. The hypothesis therefore,
(to be confirmed or refuted), is that achievement of response at the ‘molecular level’
has prognostic implications and is therefore a worthwhile aim.
Several new approaches, including the chimeric antibody anti-CD20, radio-
labelled murine anti-CD20 and the combination of Fludarabine, Mitoxantrone and
Dexamethasone have all been reported to result in ‘molecular remission’ in a propor-
tion of patients. The significance of these findings is currently unknown. High dose
treatment (Cyclophosphamide and total body irradiation) supported by autologous
haemopoietic progenitor cells has also led to ‘molecular remissions’ in some patients,
with apparent prognostic significance. The use of ‘real-time’ PCR in the future may
help to clarify the situation.
Data relating to these concepts and treatments will be discussed.
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HEPATITIS B (HBV) INFECTION, LYMPHOMA AND BONE
MARROW TRANSPLANTATION (BMT) Raymond Liang MD,
Division of Haematology and Oncology, Department of Medicine, University
of Hong Kong, Queen Mary Hospital, Hong Kong
HBV infection is endemic in many parts of Asia and Africa. In many of these places,
a chronic HBV carrier rate of over 10% is observed. The infection is predominantly
transmitted perinatally from the mother to the baby. Early contact to the virus prob-
ably has a higher chance of resulting in a chronic carrier state.
In Hong Kong, 10% of the population is serum HBsAg positive and another 40%
with the protective antibody HBsAb positive, indicating that half of the population has
had prior exposure to the virus. A similar pattern is observed in cancer patients except
lymphoma. At the time of diagnosis, at least 20% of the lymphoma patients in Hong
Kong are HBsAg positive and only 30% HBsAb positive. This may be explained by
the immunosuppressive effect of the lymphoma, resulting in about 10% of the origi-
nally HBsAb positive patients turn HBsAg positive. There is currently no evidence to
suggest that HBV infection is aetiologically related to lymphoma.
Reactivation of HBV infection is common after chemotherapy for lymphoma. As
high as 50% of the HBV carriers may develop clinical hepatitis, 10% liver failure. The
liver related mortality is about 5%. The immunosuppressive effect of the
chemotherapy results in increased viral replication in the liver. Upon cessation of the
chemotherapy and recovery of immunity, there is a marked immune mediated destruc-
tion of the heavily virus-loaded liver cells. A surge in serum HBV DNA level after
chemotherapy seems to be a good early marker of HBV reactivation. The new anti-
viral agents active against HBV, such as lamivudine, are very effective in preventing
this potentially fatal complication. Screening of HBV markers for all lymphoma
patients from endemic areas is an essential part of the protocol.
The problem is more serious if chronic HBV carriers are required to receive autol-
ogous or allogeneic stem cell or bone marrow transplantation. There is a high liver
related morbidity or mortality. Anti-viral therapy has also been shown to play an
important role in this setting. On the other hand, serological clearance of HBV has
been observed commonly after BMT in HBsAg positive recipients using HBsAb posi-
tive marrow. Transfer of humoral and cellular immunity to the patient from donor has
resulted in seroconversion from HBsAg to HBsAb positivity.8 Invited Papers
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EPSTEIN-BARR VIRUS POSITIVE LYMPHOMAS: PROSPECTS
FOR IMMUNOTHERAPY Alan Rickinson, CRC Institute for Cancer
Studies, University of Birmingham, UK S22
WHY DO WE DO WHAT WE DO? A LOOK AT THE RATIONALE,
INDICATIONS AND PERSPECTIVES OF RADIOTHERAPY Jens
Overgaard, Danish Cancer Society, Department of Experimental Clinical
Oncology, Aarhus University Hospital, Aarhus C, Denmark
Despite significant focus on education, evidence-based medicine, and other attempts
to develop rational therapeutic strategies in cancer treatment, the practice of radio-
therapy widely differs among departments and national policies. With this in mind, the
indications, rationale, and strategies for optimal radiotherapy will be discussed in the
light of recent development in technical and biological skills.
Radiotherapy is, next to surgery, the most important curative modality in cancer
treatment. Thus more than 80 percent of cancer cures are obtained with these two
loco-regional modalities, either alone or combined. At present approx. half of all
cancer patients will receive radiotherapy, either as a part of their primary treatment
and/or in palliative settings. The role of radiotherapy is increasing due to new indica-
tions and attempt to conserve organs and functions. This can be seen in new thera-
peutic strategies of e.g. early breast cancer, head and neck carcinoma, colo-rectal
carcinoma and prostate cancer, and importantly, palliation. The development in radio-
therapy has throughout the century been alternating between technical improvement
and biological optimization. Thus the last decade did especially result in an improved
technical ability to focus high dose delivery of accurate radiation, especially due to
improvement in computer and imaging technology. The upcoming years will in
contrast be expected to utilize the new molecular biological knowledge in an attempt
to understand and take advantage of the fundamental mechanisms of the radiation
effects. This will among others be directed towards reducing the dose-limiting
morbidity.
Thus, the focus on cancer in the start of the new millennium will be maintained on
the current loco-regional treatment modalities, but under influence of recent and
expected achievements in technical and biological knowledge. Utilization of such
improvements will request a responsive community of well, and continuously,
educated cancer specialists working in a multi-disciplinary and multi-institutional
team work.
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ROLE OF TGFb SIGNALING IN SKIN CARCINOGENESIS Cindy
Go1, Brian Weeks1, Wei He2, Kristin M Liefer3, Tongyu Cao3, and
Xiao-Jing Wang2,3 Department of 1Otolaryngology, 2Dermatology, 3Molecular
and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
The TGFb signaling pathway is one of the most important mechanisms in the mainte-
nance of epithelial homeostasis. Alterations leading to either the repression or
enhancement of this pathway affect cancer development. We have examined expres-
sion of TGFb signaling components during skin chemical carcinogenesis, and found
that although TGFb1 was overexpressed, TGFb receptors or signaling Smads were
lost. To further understand the pathological consequence of these changes, we have
generated complimentary transgenic mouse models, which express either a dominant
negative TGFb type II receptor (DbRII) or TGFb1 in the epidermis. The DbRII mice
exhibited an increased susceptibility to a chemical carcinogenesis protocol, with
increased tumor formation and early metastasis. DbRII tumor cells showed acceler-
ated aberrant cell cycle progression compared to tumors developing in non-transgenic
mice. Consistently, DbRII tumors showed reduced expression of p15, p21 and p27,
inhibitors of cyclin-dependent kinases (cdks). Although gDbRII tumors exhibited
early metastasis, most DbRII carcinomas did not exhibit chromosome instability, but
exhibited increased angiogenesis and matrix metalloproteinases, which correlated
with overexpression of the endogenous TGFb1. These data suggest that tumors which
possess both elevated TGFb and loss of functional TGFb receptor may have poor
prognosis, i.e., the mutant TGFb receptor allows tumor cells to escape from TGFb-
induced growth arrest, whereas elevated endogenous TGFb facilitates tumor invasion
via a paracrine effect. This hypothesis is now being further tested by utilizing the
gene-switch-TGFb1 mice, which allow the induction of TGFb1 transgene expression
at different stages of skin carcinogenesis.
1 Go C, Li, P, Wang XJ (1999). Blocking TGFb signalling in transgenic
epidermis accelerates chemical carcinogenesis via mechanisms associated with
aberrant cell cycle progression and angiogenesis. Cancer Res 59: 2861–2868
2 Wang XJ, Liefer KM, Tsai S, O’Malley BW, Roop DR (1999) Development of
Gene-Switch mice which inducibly express transforming growth factor b1
(TGFb1) in the epidermis. Proc Natl Acad Sci, USA 96: 8483–8488
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KERATIN K10, FROM CELL STRUCTURE TO CELL CYCLE
THROUGH SIGNAL TRANSDUCTION JM Paramio, C Segrelles,
MIL Casanova, M Santos, S Ruiz and JL Jorcano Dept of Cell and Molecular
Biology. CIEMAT. Av. Complutense 22, E-28040 Madrid, Spain
The members of the large keratin family of cytoskeletal proteins are expressed in a
precisely regulated tissue- and differentiation stage-specific manner. Although these
proteins are thought to be involved in conferring mechanical integrity to epithelial
cells, the functional significance of their complex differential expression is still
unclear. In epidermis, basal proliferative keratinocytes express K14; when they termi-
nally differentiate, keratinocytes switch off K14 and start K10 expression, whereas in
response to hyperproliferative stimuli, K16 replaces K10.
We have recently demonstrated that the ectopic expression of K10 inhibits prolif-
eration of human keratinocytes in culture, whilst K16 expression appears to promote
proliferation of these cells. In addition, K10-induced inhibition can be reversed by co-
expression of K16, but not K14. The mechanism by which K10 inhibits cell prolifera-
tion is linked to the retinoblastoma pathway. We found that this effect on cell cycle
progression can be attributed to alterations in the PI-3 kinase signal transduction
pathway mediated by the physical interaction between the non a-helical aminoter-
minal domain of K10 and Akt/PKB and aPKCz. This interaction prevents the trans-
location of these signalling molecules, thus impairing their activation. Finally, to
confirm these data in vivo, we generated transgenic mice in which K10 expression
was ectopically targeted to the basal layer of the epidermis. These mice showed
striking alterations in epidermal proliferation and differentiation, and displayed a
highly decreased sensitivity to skin chemical carcinogenesis. The biochemical
analysis of this phenotype was in agreement with the in vitro results.S25
GENETIC MODELS FOR SKIN CANCER Petra Boukamp, DKFZ,
Heidelberg, Germany
Despite an increasing number and agressiveness of non-melanoma skin cancer rela-
tively little is known about specific genetic aberrations and their underlying mecha-
nisms. We have developed an in vitro model of skin carcinogenesis starting with the
spontaneously immortalized human HaCaT skin keratinocytes. In this model, muta-
tional inactivation of p53, aneuploidy and particularly loss of chromosome 3p (intro-
duction of a normal copy of chromosome 3 can revert immortality), as well as
telomerase upregulation were early events, correlating with immortalization. Tumor
progression could be induced by introduction of the Harvey-ras oncogene as well as
by long-term treatment of these cells with increased temperature. This latter treatment
caused DNA strand breaks which resulted in genomic instability and a tumorigenic
phenotype which was correlated with gain of chromosomal material of 11q13 and
overexpression of cyclin D1, mapped to 11q13. In both cases, the tumor phenotype
depended on the recipient cell. Early passage HaCaT cells developed benign tumors
and late passage cells malignant tumors when injected s.c. into nude mice suggesting
that the Ha-ras gene as well as the 11q13 amplification were responsible for unre-
stricted benign-tumorigenic growth but not malignancy. Malignant conversion, on the
other hand, could be related to loss of a copy of chromosome 15. By using a skin
squamous cell carcinome cell line, SCL-I we were able to demonstrate that loss of
chromosome 15 was causal for tumorigenic progression by reducing the level of
thrombospondin 1, mapped to 15q15, and by allowing tumor vascularization and
invasive growth. Thus, loss of chromosome 15 was responsible for the angiogenic
switch during tumor progression.
In agreement, an in vivo skin progression model (MET lines derived from a
primary-, recurrent- and metastatic lesion) showed aneuploidy, loss of 3p, and gain of
11q13. Polyploidization, common in cultured cell lines, was only seen in the cell line
established from the metastasis indicating that polyploidization may be a late event in
skin carcinogenesis in man. Interestingly, all MET cells were wildtype for p53 (the
first SCC lines) and all ras genes and were deficient of HPV thus, making them the
first model to study p53 alternative pathways in skin cancer.
S26
THE SEARCH FOR EPIDERMAL STEM CELLS Fiona M Watt,
Imperial Cancer Research Fund, London WC2A 3PX, UK
The epidermis is renewed throughout adult life through proliferation of a subpopula-
tion of cells in the basal layer, known as stem cells. Stem cells have the capacity to
self-renew and also to generate daughter cells that undergo terminal differentiation.
Human epidermal stem cells can be maintained in culture and this makes it possible to
evaluate potential markers of the stem cell compartment and to identify factors that
regulate stem cell fate. I shall describe recent progress in identifying stem cell markers
and in using these to reveal the highly patterned distribution of the cells in normal
human epidermis. I shall also describe factors that act cell-autonomously to regulate
stem cell self-renewal and factors that mediate interactions between stem cells and
other basal layer cells. Finally I shall compare human epidermal stem cells in vitro
with stem cells in vivo, in transgenic mouse epidermis.
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ANALYSIS OF TUMOUR SUSCEPTIBILITY USING MOUSE
MODELS OF HUMAN CANCER Allan Balmain, Rosemary
Akhurst, Martin Oft, Hiroki Nagase, Jian Hua Mao
Much of our knowledge of the processes of multistage carcinogenesis has come from
studies of rodent models in which both the genetic background of the host and the
etiology of tumor development  can be carefully controlled. Studies of skin tumor-
genesis have identified many of the somatic genetic changes in tumor initiation and
progression, the biological events associated with these genetic alterations, and the
role of host genetic background in determining tumor susceptibility. Genetic changes
in skin carcinogenesis in the mouse resemble those seen in human squamous carci-
nomas, and include point mutations in ras and p53, and deletions at the p16INK4
locus. The rodent models have allowed us to determine the stages at which these
changes occur, and to demonstrate the importance of the target cell (stem cell or
committed cell) in which mutations take place. Quantitative changes in signal strength
through the ras pathway are also important as tumors progress to malignancy.
Studies of cell lines derived from different stages of carcinogenesis have allowed
us to identify co-operative interactions between ras and TGFb signalling pathways in
the control of tumor metastasis. Finally, the use of classical mouse genetic approaches
has led to the identification of multiple loci in the mouse genome that are polymorphic
between different mouse strains, and have major effects on germline susceptibility to
tumors induced by exposure to carcinogens. These mouse models provide us with a
novel route to the identification of tumor modifier genes that have implications for
future approaches to prevention, diagnosis and therapy of human cancers.
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